Cordeiro, Maria Francesca;
Gandolfi, Stefano;
Gugleta, Konstantin;
Normando, Eduardo M;
Oddone, Francesco;
(2023)
How latanoprost changed glaucoma management.
Acta Ophthalmologica
10.1111/aos.15725.
(In press).
Preview |
Text
How latanoprost changed glaucoma management.pdf - Published Version Download (671kB) | Preview |
Abstract
Glaucoma is currently considered one of the leading causes of severe visual impairment and blindness worldwide. Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, with an entirely new mechanism of action from that of the antiglaucoma drugs used up to that time was a very important milestone. Since then, due mainly to their efficacy, limited systemic side effects and once daily dosing, prostaglandin analogues (PGAs) have become as the first-choice treatment for primary open-angle glaucoma. PGAs are in general terms well tolerated, although they are associated with several mild to moderate ocular and periocular adverse events. Among them, conjunctival hyperemia, eyelash changes, eyelid pigmentation, iris pigmentation and hypertrichosis around the eyes are the most prevalent. The objective of this paper is to review the role of PGAs in the treatment of glaucoma over the 25 years since the launch of Latanoprost and their impact on clinical practice outcomes.
| Type: | Article |
|---|---|
| Title: | How latanoprost changed glaucoma management |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/aos.15725 |
| Publisher version: | https://doi.org/10.1111/aos.15725 |
| Language: | English |
| Additional information: | © 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Latanoprost, glaucoma, medical treatment, open-angle glaucoma, progression, prostaglandin analogues |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10172820 |
Archive Staff Only
 |
View Item |
